SCHEMBL1492489

SCHEMBL1492489

C[Si](C)(C)CCS(=O)(=O)O.[NaH]

nearest known ligand 0.39

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.39
PDE4A P27815 1/20 0.39
LMNA P02545 1/20 0.39
SLC6A6 P31641 1/20 0.39
CYP2C19 P33261 1/20 0.39
BLM P54132 1/20 0.39
APP P05067 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1825217 0.97 PTGS1 (0.41) PTGS1PDE4ALMNASLC6A6CYP2C19
SCHEMBL4300905 0.84 APP (0.44) PTGS1PDE4ALMNASLC6A6CYP2C19
SCHEMBL424022 0.84 APP (0.44) PTGS1PDE4ALMNASLC6A6CYP2C19
Water SCHEMBL429998 0.82 APP (0.42) PTGS1PDE4ALMNASLC6A6CYP2C19
SCHEMBL395722 0.81 APP (0.46) PTGS1PDE4ALMNASLC6A6CYP2C19
SCHEMBL29462018 0.79 APP (0.44) PTGS1PDE4ALMNASLC6A6CYP2C19
Hydrochloric Acid SCHEMBL5070335 0.79 APP (0.44) PTGS1PDE4ALMNASLC6A6CYP2C19
SCHEMBL2187038 0.77 APP (0.42) PTGS1PDE4ALMNASLC6A6CYP2C19
SCHEMBL6723728 0.73 APEX1 (0.30)
SCHEMBL920488 0.71 PTGS1 (0.56) PTGS1PDE4ALMNASLC6A6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3565017-B1 ELECTROCHEMICAL LIGHT EMITTING CELL JAPAN ADVANCED INSTITUTE OF SCIENCE AND TECH (JP) 2022-07-20 EP disclosed
CN-110121795-B Electrochemical light-emitting cell 国立大学法人北陆先端科学技术大学院大学 2021-09-24 CN disclosed
CN-107532100-B Lubricant comprising silicon-containing ionic liquid 日清纺控股株式会社 2020-10-02 CN disclosed
EP-3296381-B1 LUBRICANT INCLUDING SILICON-CONTAINING IONIC LIQUID NISSHINBO HOLDINGS INC (JP) 2020-07-15 EP disclosed
US-10658700-B2 Additive for electrolyte solutions NISSHINBO HOLDINGS INC. (JP) 2020-05-19 US disclosed
US-10619117-B2 Lubricant including silicon-containing ionic liquid NISSHINBO HOLDINGS INC. (JP) 2020-04-14 US disclosed
EP-3565017-A1 ELECTROCHEMICAL LIGHT EMITTING CELL Japan Advanced Institute of Science and Technology (JP) 2019-11-06 EP disclosed
US-20190316738-A1 LIGHT-EMITTING ELECTROCHEMICAL CELL NISSHINBO HOLDINGS INC. (JP) 2019-10-17 US disclosed
US-20180269529-A1 ADDITIVE FOR ELECTROLYTE SOLUTIONS NISSHINBO HOLDINGS INC. (JP) 2018-09-20 US disclosed
EP-2910558-B1 IONIC LIQUID NISSHINBO HOLDINGS INC (JP) 2018-08-08 EP disclosed
WO-2007008472-A2 PHOTOINDUCED SIGNAL AMPLIFICATION THROUGH EXTERNALLY SENSITIZED PHOTOFRAGMENTATION IN MASKED PHOTOSENSITIZERS COLORADO SEMINARY, WHICH OWNS AND OPERATES THE UNIVERSITY OF DENVER (US) 2007-01-18 WO disclosed
EP-1730137-A1 HETEROCYCLIC CGRP ANTAGONISTS FOR THE TREATMENT OF MIGRAINE Bristol-Myers Squibb Company (US) 2006-12-13 EP disclosed
EP-1689493-A1 CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS Bristol-Myers Squibb Pharma Company (US) 2006-08-16 EP disclosed
WO-2005095383-A1 HETEROCYCLIC CGRP ANTAGONISTS FOR THE TREATMENT OF MIGRAINE BRISTOL-MYERS SQUIBB COMPANY (US) 2005-10-13 WO disclosed
US-20050215576-A1 Novel therapeutic agents for the treatment of migraine BRISTOL-MYERS SQUIBB COMPANY 2005-09-29 US disclosed
WO-2005065779-A1 CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2005-07-21 WO disclosed
EP-1539766-A1 CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS Bristol-Myers Squibb Company (US) 2005-06-15 EP disclosed
US-20040204397-A1 Calcitonin gene related peptide receptor antagonists BRISTOL-MYERS SQUIBB COMPANY 2004-10-14 US disclosed
US-20040063735-A1 Calcitonin gene related peptide receptor antagonists BRISTOL-MYERS SQUIBB COMPANY 2004-04-01 US disclosed
WO-2003104236-A1 CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063735-A1 Calcitonin gene related peptide receptor antagonists CALCRL, CALCA, CALCR PTGS1 63/4885PDE4A 1537/4885LMNA 2724/4885
US-20050215576-A1 Novel therapeutic agents for the treatment of migraine CALCRL, CALCR, CALCA PTGS1 94/4885PDE4A 707/4885LMNA 3181/4885
US-10619117-B2 Lubricant including silicon-containing ionic liquid MUC1, CCR1, TAS1R1 PTGS1 2279/4885PDE4A 4836/4885LMNA 3650/4885
US-20040204397-A1 Calcitonin gene related peptide receptor antagonists CALCRL, CALCA, CALCR PTGS1 63/4885PDE4A 1537/4885LMNA 2724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.